Akari Therapeutics to Participate in the Sidoti November 2022 Virtual Micro-Cap ConferenceGlobeNewsWire • 10/31/22
Akari Therapeutics Announces Receipt of Nasdaq Minimum Bid Price NotificationGlobeNewsWire • 10/28/22
Akari Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Pipeline ProgressGlobeNewsWire • 09/27/22
Akari Therapeutics Announces Positive Results from Recent Pre-Clinical Studies of Investigational PASylated® Nomacopan That Support the Potential to Advance Research Toward IND/IMPD for Clinical Trials in Geographic AtrophyGlobeNewsWire • 07/28/22
Akari Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Pipeline ProgressGlobeNewsWire • 07/20/22
Akari Therapeutics Announces First Patient to Complete Course of Treatment in the Phase III Part A Clinical Trial of Investigational Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA)GlobeNewsWire • 07/07/22
Akari Therapeutics Announces the Appointment of Accomplished Biotech Executive Melissa Bradford-Klug as Chief Operating Officer to Lead Business Development and Company Growth StrategiesGlobeNewsWire • 06/13/22
Akari Therapeutics Presents Results from the CASCADE and CORONET Studies in COVID-19 at the American Thoracic Society (ATS) 2022 Annual MeetingGlobeNewsWire • 05/19/22
Akari Therapeutics Reports Full Year 2021 Financial Results and Highlights Clinical ProgressGlobeNewsWire • 05/16/22
Akari Therapeutics to Present Results from Compassionate Use of Nomacopan for COVID-19 (CORONET) and Identification of Clinical Deterioration Risk in COVID-19 (CASCADE) at the American Thoracic Society (ATS) 2022 Annual MeetingGlobeNewsWire • 05/11/22
Akari Therapeutics Announces Publication of Phase II Data of Investigational Nomacopan for the Treatment of Bullous Pemphigoid (BP) in JAMA DermatologyGlobeNewsWire • 05/10/22
Akari Presents Results from Two Preclinical Development Programs of Long-Acting PAS-Nomacopan in Geographic Atrophy (GA) Dry Age-Related Macular Degeneration and Nomacopan in Experimental Immune-Mediated Conjunctival Disease (EIC)GlobeNewsWire • 05/09/22
Akari Therapeutics to Present on Two Ongoing Programs Covering Age-Related Macular Degeneration and Diseases of the Surface of the Eye at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual MeetingGlobeNewsWire • 03/21/22
Akari Therapeutics Announces New Data Supporting Use of Drug Candidate Votucalis Targeting Difficult to Treat Pain and ItchGlobeNewsWire • 03/09/22
Akari Therapeutics Appoints Rachelle Jacques as President and Chief Executive OfficerGlobeNewsWire • 03/02/22
Akari Therapeutics Announces New Data Showing A Significant Role for Complement Activation in the Clinical Outcomes of U.S. Army Trauma Patients in Iraq and the Therapeutic Potential of Nomacopan for Treatment of TraumaGlobeNewsWire • 02/28/22
Akari Advances Lung Program with Inhaled Nomacopan Focused on Early Treatment of Severe Exacerbations in Lung DiseasesGlobeNewsWire • 01/26/22
FDA Agrees to Use of New Higher-Yielding Manufacturing Process for Nomacopan in Pivotal Clinical StudiesGlobeNewsWire • 01/19/22
Akari Therapeutics to Present at H.C. Wainwright BioConnect Virtual ConferenceGlobeNewsWire • 01/04/22
